knowledge -WSS

knowledge

author：entertainment 2025-10-01 00:05:34 - browse：72

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

WSS

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Colorectal cancer study finds potential in overlooked immune cell

Stroke deaths set to near 10 million globally by 2050

Reports of telehealth's death have been greatly exaggerated

ASCO eve: Let’s set the table for this year's meeting

UnitedHealth argues against case alleging wrongful AI care denials

focus

knowledge

leisure time

In Memoriam: Notable people who died in 2023

Eyeing GLP

Psychedelics group wrestles with new pharma identity

Stroke deaths set to near 10 million globally by 2050

Psychedelics group wrestles with new pharma identity

Colorectal cancer study finds potential in overlooked immune cell

Heart attack and stroke risk calculators need revising

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Apple is now the first public company to be valued at $3 trillion

Why Charlie Gard's case is so disturbing to Americans

focus

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Bill would stop addiction treatment from triggering child abuse inquiry

Scrutiny of post

What to expect at HLTH 2023, the health care industry conference

Questions and answers about ramping up H5N1 bird flu vaccine

entertainment

focus

explore

leisure time